Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pembrolizumab/quavonlimab - Merck Sharp & Dohme

Next Previous
Drug Profile

Pembrolizumab/quavonlimab - Merck Sharp & Dohme

Alternative Names: Coformulation Pembrolizumab/quavonlimab - Merck Sharp & Dohme; MK 1308A; Pembrolizumab+quavonlimab; Quavonlimab+pembrolizumab; Quavonlimab/pembrolizumab - Merck Sharp & Dohme

Latest Information Update: 12 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Eisai Inc; Merck Sharp & Dohme
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase II Colorectal cancer; Liver cancer; Malignant melanoma; Small cell lung cancer; Solid tumours

Most Recent Events

  • 18 May 2026 Merck Sharp & Dohmecompletes a phase-I/II clinical trials in Malignant melanoma (Late-stage disease, First-line therapy, Inoperable/Unresectable) in USA, Argentina, Australia, Chile, Colombia, France, Greece, Hungary, Israel, Italy, Poland, South Africa, Spain, Switzerland (IV, Infusion) (NCT04305054)
  • 28 Feb 2026 Updated efficacy and adverse events data from a phase I/II KEYMAKER-U03 substudy 03B trial in Renal cell carcinoma presented at the 2026 Genitourinary Cancers Symposium (ASCO-GeCS-2026)
  • 10 Jan 2026 Efficacy and adverse events data from a phase II trial in colorectal cancer presented at the 2026 Gastrointestinal Cancers Symposium (ASCO-GI-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top